April 19, 2014 11:55 AM ET

Pharmaceuticals

Company Overview of Noven Pharmaceuticals, Inc.

Company Overview

Noven Pharmaceuticals, Inc. researches, develops, manufactures, markets, and sells prescription pharmaceutical products. Its products include Vivelle-Dot and Estradot, which are transdermal estrogen patches; CombiPatch and Estalis, which are combination estrogen/progestogen patches; Stavzor, a delayed release valproic acid softgel; Pexeva, a paroxetine mesylate; Lithobid, a lithium carbonate; Brisdelle, a paroxetine capsule for the treatment of vasomotor symptoms associated with menopause; and Daytrana, a methylphenidate transdermal system. It also manufactures Daytrana, a prescription central nervous system stimulant patch system for the treatment of ADHD in the age group of 6 to 17 years o...

11960 SW 144th Street

Miami, FL 33186

United States

Founded in 1987

610 Employees

Phone:

305-253-5099

Fax:

305-251-1887

Key Executives for Noven Pharmaceuticals, Inc.

Chief Executive Officer and President
Age: 47
Chief Financial Officer
Age: 55
Vice President of Operations
Age: 62
Chief Scientific Officer and Vice President
Age: 57
Chief Medical Officer and Executive Vice President of Product Development
Age: 58
Compensation as of Fiscal Year 2013.

Noven Pharmaceuticals, Inc. Key Developments

Noven Pharmaceuticals, Inc. Announces Settlement of Lidoderm(R) Patent Litigation with Endo Pharmaceuticals Inc., Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc

Noven Pharmaceuticals, Inc. announced that it has entered into an agreement with Endo Pharmaceuticals Inc., Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. to settle all outstanding patent litigation related to Noven's lidocaine topical patch 5% product. An Abbreviated New Drug Application for Noven's product is currently pending at the U.S. Food and Drug Administration (FDA). If approved, Noven's product would be a generic version of Endo's Lidoderm(R). The agreement allows Noven to launch its generic Lidoderm(R) product on or after March 1, 2015, if the product is approved by the FDA. The agreement provides for an earlier launch under certain circumstances. Pursuant to the agreement, the litigation on this matter, currently pending in U.S. District Court for the District of Delaware, will be dismissed. Other terms of the settlement were not disclosed. The settlement agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.

Actavis plc Enters an Agreement with Noven Pharmaceuticals, Inc. to Settle all Outstanding Patent Litigation

Actavis plc announced that it has entered into an agreement with Noven Pharmaceuticals, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Daytrana (Methylphenidate Transdermal System). Daytrana is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder. Under the terms of the agreement, Noven will grant Actavis a non-exclusive, royalty-bearing license to market its generic Daytrana beginning on September 1, 2015, or earlier under certain circumstances.

Noven Pharmaceuticals Announces Brisdelle(TM) (Paroxetine) Capsules, 7.5 Mg

Noven Pharmaceuticals, Inc. announced that Brisdelle(TM) (paroxetine) capsules, 7.5 mg, is now available by prescription nationwide. Brisdelle is the first and only FDA-approved, non-hormonal treatment for moderate to severe vasomotor symptoms (VMS) associated with menopause, commonly referred to as hot flashes. The availability of Brisdelle offers women with moderate to severe hot flashes an FDA-approved, non-hormonal choice, helping to advance treatment options for menopausal women. Moderate to severe hot flashes -- sudden feelings of intense heat in the body that include sweating -- affect millions of menopausal women in the United States. Previously, hormone therapy was the only FDA-approved treatment for hot flashes associated with menopause and, because many women are unable or unwilling to take hormone therapy, symptoms were often left untreated.

Similar Private Companies By Industry

Company Name Region
Immunogenetics, Inc United States
Green Cannabis Collective, Inc. United States
Panacela Labs, Inc. United States
Sirion Therapeutics, Inc. United States
Cornerstone BioPharma Holdings, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Noven Pharmaceuticals, Inc., please visit www.noven.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.